{"id":"F2010L00128","name":"National Health Act 1953 - Determination made pursuant to subsections 99ADB(4) and 99ADB(5) (No. PB 13 of 2010)","slug":"national-health-act-1953-determination-made-pursuant-to-subsections-99adb-4-and-99adb-5-no-pb-13-of-","collection":"legislative_instrument","jurisdiction":"commonwealth","status":"repealed","isInForce":false,"actNumber":null,"makingDate":null,"administeringDepartment":null,"currentVersion":{"id":122861,"registerId":"commonwealth-F2010L00128-current","compilationNumber":null,"startDate":"2026-04-03","status":"Repealed","reasons":null,"registeredAt":null},"sections":[{"sectionNumber":"1","sectionType":"section","heading":"National Health Act 1953 - Determination made pursuant to subsections 99ADB(4) and 99ADB(5) (No. PB 13 of 2010)","content":"![](image.001.png)\n\nCOMMONWEALTH OF AUSTRALIA\n\nInstrument number PB 13 of 2010\n\nDetermination made pursuant to subsections 99ADB(4) and 99ADB(5) of the National Health Act 1953\n\nData collection period from 1 September 2008 to 31 August 2009 (inclusive)\n\nI, Felicity McNeill, delegate of the Minister for Health and Ageing:\n\nDETERMINE pursuant to subsection 99ADB(4) of the National Health Act 1953 (“the Act”) and in accordance with the National Health (Pharmaceutical Benefits) Regulations 1960 (“the Regulations”), that the weighted average disclosed price specified in column 3 of an item in Schedule 1 is the weighted average disclosed price for the brand of pharmaceutical item specified in column 2 of the same item in Schedule 1.\n\nDETERMINE pursuant to subsection 99ADB(5) of the Act, in accordance with the Regulations, that the weighted average disclosed price specified in column 3 of an item in Schedule 2 is the weighted average disclosed price for the brand of pharmaceutical item specified in column 2 of the same item in Schedule 2.\n\nThis instrument commences on the later of the following:\n\n(a) immediately after the commencement of PB 12 of 2010;\n\n(b) the day after it is registered.\n\nDated 22 January 2010\n\nFelicity McNeill\n\n\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\n\nFelicity McNeill\n\nAssistant Secretary\n\nPharmaceutical Evaluation Branch\n\nDepartment of Health and Ageing\n\nSchedule 1\n\n```html\n

Column 1

Column 2

Column 3

Item

Brand of Pharmaceutical Item

Weighted average disclosed price

Listed Drug

Form

Manner of administration

Brand

1

Cefalotin

Powder for injection 1 g (as sodium)

Injection

Cefalotin Sandoz

$16.03

2

Doxorubicin

Solution for I.V. injection or intravesical administration containing doxorubicin hydrochloride 200 mg in 100 mL single dose vial

Injection/intravesical

Adriamycin

$116.27

3

Meloxicam

Tablet 7.5 mg

Oral

GenRx Meloxicam

$10.19

4

Mitozantrone

Injection 10 mg (as hydrochloride) in 5 mL

Injection

Mitozantrone Ebewe

$73.00

5

Ondansetron

I.V. injection 4 mg (as hydrochloride dihydrate) in 2 mL

Injection

Pfizer Australia Pty Ltd

$10.93

\n```\n\nSchedule 2\n\n```html\n

Column 1

Column 2

Column 3

Item

Brand of Pharmaceutical Item

Weighted average disclosed price

Listed Drug

Form

Manner of administration

Brand

1

Cefalotin

Powder for injection 1 g (as sodium)

Injection

Hospira Pty Limited

$16.03

2

Cefalotin

Powder for injection 1 g (as sodium)

Injection

Keflin Neutral

$16.03

3

Doxorubicin

Solution for I.V. injection or intravesical administration containing doxorubicin hydrochloride 10 mg in 5 mL single dose vial

Injection/intravesical

Adriamycin Solution

$6.88

4

Doxorubicin

Solution for I.V. injection or intravesical administration containing doxorubicin hydrochloride 20 mg in 10 mL single dose vial

Injection/intravesical

Adriamycin Solution

$12.30

5

Doxorubicin

Solution for I.V. injection or intravesical administration containing doxorubicin hydrochloride 50 mg in 25 mL single dose vial

Injection/intravesical

Adriamycin Solution

$29.07

6

Doxorubicin

Solution for I.V. injection or intravesical administration containing doxorubicin hydrochloride 10 mg in 5 mL single dose vial

Injection/intravesical

Doxorubicin Ebewe

$6.88

7

Doxorubicin

Solution for I.V. injection or intravesical administration containing doxorubicin hydrochloride 50 mg in 25 mL single dose vial

Injection/intravesical

Doxorubicin Ebewe

$29.07

8

Doxorubicin

Solution for I.V. injection or intravesical administration containing doxorubicin hydrochloride 100 mg in 50 mL single dose vial

Injection/intravesical

Doxorubicin Ebewe

$ 156.26

9

Doxorubicin

Solution for I.V. injection or intravesical administration containing doxorubicin hydrochloride 200 mg in 100 mL single dose vial

Injection/intravesical

Doxorubicin Ebewe

$116.27

10

Doxorubicin

Solution for I.V. injection or intravesical administration containing doxorubicin hydrochloride 10 mg in 5 mL single dose vial

Injection/intravesical

Hospira Pty Limited

$6.88

11

Doxorubicin

Solution for I.V. injection or intravesical administration containing doxorubicin hydrochloride 50 mg in 25 mL single dose vial

Injection/intravesical

Hospira Pty Limited

$29.07

12

Meloxicam

Tablet 15 mg

Oral

GenRx Meloxicam

$14.87

13

Meloxicam

Tablet 7.5 mg

Oral

Chem mart Meloxicam 7.5 mg

$10.19

14

Meloxicam

Tablet 15 mg

Oral

Chem mart Meloxicam 15 mg

$14.87

15

Meloxicam

Tablet 7.5 mg

Oral

Terry White Chemists Meloxicam 7.5mg

$10.19

16

Meloxicam

Tablet 15 mg

Oral

Terry White Chemists Meloxicam 15mg

$14.87

17

Meloxicam

Tablet 7.5 mg

Oral

Moxicam 7.5

$10.19

18

Meloxicam

Tablet 15 mg

Oral

Moxicam 15

$14.87

19

Meloxicam

Tablet 7.5 mg

Oral

Meloxibell

$10.19

20

Meloxicam

Tablet 15 mg

Oral

Meloxibell

$14.87

21

Meloxicam

Tablet 7.5 mg

Oral

Mobic

$10.19

22

Meloxicam

Tablet 15 mg

Oral

Mobic

$14.87

23

Meloxicam

Capsule 7.5 mg

Oral

Mobic

$10.19

24

Meloxicam

Capsule 15 mg

Oral

Mobic

$14.87

25

Meloxicam

Tablet 7.5 mg

Oral

Meloxicam-GA

$10.19

26

Meloxicam

Tablet 15 mg

Oral

Meloxicam-GA

$14.87

27

Meloxicam

Tablet 7.5 mg

Oral

Pharmacor Meloxicam 7.5

$10.19

28

Meloxicam

Tablet 15 mg

Oral

Pharmacor Meloxicam 15

$14.87

29

Meloxicam

Tablet 7.5 mg

Oral

Meloxicam Ranbaxy

$10.19

30

Meloxicam

Tablet 15 mg

Oral

Meloxicam Ranbaxy

$14.87

31

Meloxicam

Tablet 7.5 mg

Oral

Meloxicam Sandoz

$10.19

32

Meloxicam

Tablet 15 mg

Oral

Meloxicam Sandoz

$14.87

33

Meloxicam

Tablet 7.5 mg

Oral

Meloxicam Winthrop

$10.19

34

Meloxicam

Tablet 15 mg

Oral

Meloxicam Winthrop

$14.87

35

Meloxicam

Tablet 7.5 mg

Oral

Movalis 7.5

$10.19

36

Meloxicam

Tablet 15 mg

Oral

Movalis 15

$14.87

37

Meloxicam

Capsule 7.5 mg

Oral

Movalis 7.5

$10.19

38

Meloxicam

Capsule 15 mg

Oral

Movalis 15

$14.87

39

Mitozantrone

Injection 20 mg (as hydrochloride) in 10 mL

Injection

Mitozantrone Ebewe

$146.00

40

Mitozantrone

Injection 10 mg (as hydrochloride) in 5 mL

Injection

Pfizer Australia Pty Ltd

$73.00

41

Mitozantrone

Injection 20 mg (as hydrochloride) in 10 mL

Injection

Pfizer Australia Pty Ltd

$146.00

42

Mitozantrone

Injection 25 mg (as hydrochloride) in 12.5 mL

Injection

Pfizer Australia Pty Ltd

$182.40

43

Mitozantrone

Injection 20 mg (as hydrochloride) in 10 mL

Injection

Hospira Australia Pty Ltd

$146.00

44

Mitozantrone

Injection 20 mg (as hydrochloride) in 10 mL

Injection

Onkotrone

$146.00

45

Mitozantrone

Injection 25 mg (as hydrochloride) in 12.5 mL

Injection

Onkotrone

$182.40

46

Ondansetron

I.V. injection 8 mg (as hydrochloride dihydrate) in 4 mL

Injection

Pfizer Australia Pty Ltd

$17.37

47

Ondansetron

I.V. injection 4 mg (as hydrochloride dihydrate) in 2 mL

Injection

Ondansetron-RL

$10.93

48

Ondansetron

I.V. injection 8 mg (as hydrochloride dihydrate) in 4 mL

Injection

Ondansetron-RL

$17.37

49

Ondansetron

I.V. injection 4 mg (as hydrochloride dihydrate) in 2 mL

Injection

Zofran

$10.93

50

Ondansetron

I.V. injection 8 mg (as hydrochloride dihydrate) in 4 mL

Injection

Zofran

$17.37

51

Ondansetron

I.V. injection 4 mg (as hydrochloride dihydrate) in 2 mL

Injection

Ondaz

$10.93

52

Ondansetron

I.V. injection 8 mg (as hydrochloride dihydrate) in 4 mL

Injection

Ondaz

$17.37

53

Ondansetron

I.V. injection 4 mg (as hydrochloride dihydrate) in 2 mL

Injection

Onsetron

$10.93

54

Ondansetron

I.V. injection 8 mg (as hydrochloride dihydrate) in 4 mL

Injection

Onsetron

$17.37

\n```\n\n\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\n\nNote\n\n1. All legislative instruments and compilations are registered on the Federal Register of Legislative Instruments kept under the Legislative Instruments Act 2003. See [http://www.frli.gov.au](http://www.frli.gov.au)","sortOrder":0}],"analysis":{"kimi_summary":{"_metrics":{"model":"kimi-k2.5","source":"moonshot-realtime","completionTokens":2547},"content_quality":"ok","complexity_score":2,"scope_assessment":{"changed":false,"description":"This is the original instrument (PB 13 of 2010) and operates within its intended scope as a specific pricing determination for the 2008-2009 data collection period under the Pharmaceutical Benefits Scheme."},"complexity_factors":["Short, declarative instrument with no conditional logic or exceptions","Minimal cross-referencing to parent Act (only sections 99ADB(4) and (5))","Content consists entirely of tabular price data in two schedules","No definitions section or interpretive provisions"],"plain_english_summary":"This determination fixes the weighted average disclosed price (WADP) for selected PBS-listed brands using pharmacy sales data from 1 Sept 2008–31 Aug 2009 and publishes those benchmark prices in two schedules. It affects pharmaceutical companies’ reimbursements, pharmacies’ acquisition costs and ultimately patient costs. The WADP is used to set consistent, market-based subsidy rates and help control PBS expenditure."},"flash_summary":{"complexity_score":3,"scope_assessment":{"changed":false,"description":"This determination does not change the statutory reach of the National Health Act; it implements the Act’s pricing mechanism by specifying numeric weighted average disclosed prices for named brands and a fixed data‑collection period (1 Sep 2008–31 Aug 2009). The instrument is administrative and item‑specific rather than expanding coverage or creating new regulatory obligations (see ss.99ADB(4)–(5) and the commencement clause)."},"complexity_factors":["Legal form: a delegated determination under subsections 99ADB(4) and 99ADB(5) of the National Health Act 1953 (text: \"DETERMINE pursuant to subsection 99ADB(4)\" / \"99ADB(5)\") — requires correct exercise of statutory power.","Detailed schedules: two large tabular schedules listing many brands, forms and exact dollar amounts — administrative precision needed for matching items to PBS records.","Commencement linkage: operation begins on the later of commencement of PB 12 of 2010 or the day after registration (text: \"This instrument commences on the later of...\") — introduces dependency on another instrument and registry timing.","Operational impact: the prices determine downstream Scheme calculations and payments, so data accuracy affects financial flows and compliance burdens for suppliers and administrators.","Limited discretion but routine: content is numeric/specification rather than novel policy, but still reflects an administrative choice by a delegate (delegate named and office given)."],"plain_english_summary":"This instrument, made by a Ministerial delegate under the National Health Act and associated Regulations, sets the \"weighted average disclosed price\" for specified brands and formulations of listed pharmaceutical items for the data‑collection year 1 September 2008 to 31 August 2009. It supplies the numeric prices that feed into Pharmaceutical Benefits Scheme pricing and payment calculations and therefore affects listed product sponsors, wholesalers, pharmacists and the Scheme’s administrators."}},"importantCases":[],"_links":{"self":"/api/acts/national-health-act-1953-determination-made-pursuant-to-subsections-99adb-4-and-99adb-5-no-pb-13-of-","history":"/api/acts/national-health-act-1953-determination-made-pursuant-to-subsections-99adb-4-and-99adb-5-no-pb-13-of-/history","analysis":"/api/acts/national-health-act-1953-determination-made-pursuant-to-subsections-99adb-4-and-99adb-5-no-pb-13-of-/analysis","conflicts":"/api/acts/national-health-act-1953-determination-made-pursuant-to-subsections-99adb-4-and-99adb-5-no-pb-13-of-/conflicts","importantCases":"/api/acts/national-health-act-1953-determination-made-pursuant-to-subsections-99adb-4-and-99adb-5-no-pb-13-of-/important-cases","documents":"/api/acts/national-health-act-1953-determination-made-pursuant-to-subsections-99adb-4-and-99adb-5-no-pb-13-of-/documents"}}